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Rifaximin is an oral antimicrobial, semisynthetic and nonabsorbable with minimal adverse effects that act locally in the 
gastrointestinal tract. Rifaximin does not have standardized methods of analysis for the tablets evaluation in official 
compendiums. The objective of this study is to develop and validate an analytical method for the quantification of rifaximin in 
tablets by spectrophotometry in the ultraviolet region, aiming at a miniaturized and eco-friendly method. The method was 
performed using 700 μL cuvette and purified water: ethanol (4:1, v/v) as diluent. The wavelength used was 233 nm and the range 
of concentrations was 4-14 µg mL-1. It was linear with correlation coefficient greater than 0.9999, precise with relative standard 
deviation equal 0.80%, 1.19% and 1.19% for intraday, interday and interanalyst precision, respectively, exact with average 
recovery of 100.56%, selective against the presence of interferents such as impurities, matrix compounds and solvents used and 
robust with the change of ethyl alcohol brand and proportion used as diluent. The method developed presents advantages as, 
minimum waste generation, reduction in amount of sample, standard and solvents used and reduction in time of analysis. Then 
this method can be used in routine analysis of rifaximin tablets as an alternative method, reliable, effective, really fast, low cost, 
eco-friendly and miniaturized. This study contemplates a current and innovative topic which is extremely important for the area of 
Quality Control of drugs and medicines and for the sustainable Green Analytical Chemistry. 
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Introduction  
 
Rifaximin (Figure 1A) is an antimicrobial, semisynthetic 
with broad spectrum of action nonabsorbable that acts 
locally in the gastrointestinal tract with minimal systemic 
adverse effects. It is a derivative of rifamycin and a 
structural analogue of rifampicin, that acts in RNA 
polimerase inhibiting bacterial RNA synthesis (1-3). 
 
 
Figure 1. (A) Chemical structure of rifaximin (CAS 80621-81-4). 
(B) Sobreposition of standard, sample and adjuvants spectrums at 
concentration of 10 µg mL-1. 
 
The appearance of rifaximin is an orange, hygroscopic and 
crystalline powder that must be storage on places without 
light. Rifaximin is practically insoluble in water and soluble 
in acetone and methanol (4, 5). 
This medicine is used for the treatment of diseases such as 
hepatic encephalopathy (6), travelers' diarrhea (7), irritable 
bowel syndrome (8), Clostridium difficile infections (9), 
ulcerative colitis (10), bacterial vaginosis (10) and acute 
diarrhea (11). 
Despite rifaximin has been very used, it does not have 
monograph by spectrophotometric in ultraviolet region 
described in official compendiums (4, 5, 12-15). 
Quality Control is very important for pharmaceutical 
products to confront the forgery and low quality, mainly for 
medicines because it ensures the safety and efficacy of the 
patient treatment, decreases bacterial resistance and promote 
the rational use of medicines (16). Furthermore, nowadays 
the use of eco-friendly methods that use green solvents has 
been appreciated in the analysis (17-18). 
The concept of Green Chemistry started in 1990 and 
expanded quickly in Europe and the United States. The goal 
of Green Chemistry was to reduce pollution through the use 
of green solvents (19). Many companies are in agreement 
with this thought that also contemplates the idea of 
sustainability (20). 
Eco-friendly analytical methods that decrease the use of 
toxic solvents and reduce the toxic waste generation are 
valid. This is extremely profitable for both environment and 
operator (21). 
The objective of development of effective and reliable 
analytical method for the quality control is to provide 
reliable information about the nature and composition of the 
sample in analysis. Thus, several facts must be considered in 
the development of a new analytical method, for example, 
detection, reliability, separation of all compounds of interest, 
the time taken to carry out the analysis, low final cost and 
the use of green reagents (22-23). 
The validation is important to ensure the quality and to show 
that the method is suited for the proposition intended and it 
is safety to be done (24). 
The advantage of miniaturized system is low amount of 
sample, solvents and reagents, decrease time of analysis and 
mainly reduce the waste generation (25-27). In the literature 
two articles about spectrophotometric in ultraviolet region 
method were founded (28-29), however one of them uses 
toxic solvents like methanol and the other it is not 
miniaturized method as this research and therefore it does 
not contemplate the advantages mentioned above. 
Therefore, the method proposed in this work intends the 
miniaturization, the use of eco-friendly solvents, low final 
 
Drug Anal Res, 2019; v. 3, n.  02, 23-29 
 
24 
cost and to make the analysis faster. This is very interesting 
for industries and the environment. 
 
Experiments 
 
Materials 
 
The reference standard was rifaximin, content 99.0%, 
acquired from the company NutraTech Development 
Limited – (China). 
The pharmaceutical form was rifaximin tablets (labeled 
content 200 mg), lot 15718, under the trade name Flonorm 
™, from Laboratory Gonher Farmaceutica LTDA. 
The reagents tested in solubility and stability experiment 
were purified water (Milli-Q), ethyl alcohol (Synth®), 
sodium hydroxide solution (Synth®), hydrochloric acid 
solution (Qhemis®), phosphate buffer pH 3.0 and pH 6.0, 
borate buffer pH 9.0, and acetate buffer pH 3.0 with sodium 
lauryl sulfate 0.2%, all of them at concentration of 0.05 M. 
The placebo was prepared mixing amounts of excipients 
usually present in tablets, following these proportions: 
0.18% sodium carboxymethyl, 1.5% glyceryl 
palmitostearate, 1.0% colloidal anhydrous silica, 30% talc, 
20% microcrystalline cellulose, 0.4% hypromellose, 1.4% 
titanium dioxide, 0.18% disodium edentate, 0.3% propylene 
glycol, 1.0% red iron oxide. 
 
Equipment 
 
The reference standard was weighed in analytical balance 
model H51 (Mettler Toledo®), the solutions was sonicated 
in ultrasound equipment Ultrasonic Cleaner (Unique®), the 
equipment used to analyze the solution was 
Spectrophotometer UV -1800 (Shimadzu®); and quartz 
cuvettes with capacity of 700 µL and 10 mm optical path. 
 
Method Development 
 
Solubility and Stability 
 
The diluents tested in this experiment were purified water, 
solution with 10% and 20% of ethyl alcohol, sodium 
hydroxide solution with concentration 0.001 mol L-1, 
hydrochloric acid solution with concentration 0.01 mol L-1, 
phosphate buffer pH 3.0 and pH 6.0, borate buffer pH 9.0, 
and acetate buffer pH 3.0 with sodium lauryl sulfate 0.2%. 
A solution was prepared with each diluent at final 
concentration of 200 µg mL-1 using a 25 mL amber 
volumetric flask. The scanning of all solutions was made 
after 0, 4, 6, 8 and 24 hours to check the solubility and 
stability of rifaximin in these diluents. 
 
Ringbom Curve 
 
The Ringbom curve was obtained by the determination of 33 
different concentrations of standard rifaximin solution at the 
wavelength 233 nm.  
0.00505 g of standard rifaximin was weighed and 
transferred to a 25 mL amber volumetric flask. 5 mL of 
ethyl alcohol was added and this solution was kept 15 
minutes in ultrasound. After it, the volume was completing 
with purified water to obtain a final concentration of 200 µg 
mL-1. It was filtered through filter paper and from this 
solution aliquots was transferred to a 2 mL amber 
volumetric flask, completing the volume with solution of 
purified water and 20% ethyl alcohol to get 33 
concentrations from 0.2 to 200 µg mL-1. 
 
Sample weight 
 
Twenty individually tablets were weighted and were 
macerated in a porcelain mortar and stocked to use it in 
validation parameters: selectivity and accuracy. 
 
Method Validation 
 
National and international guides were used in the validation 
of the method (24, 30-31). 
 
Selectivity 
 
The selectivity is the capacity of the method to identify or 
quantify the substance of interest, even in the presence of 
other compounds that can be in the sample (30). 
In this method, the selectivity was confirmed by the 
sobreposition of the standard, sample, and adjuvants 
spectrum. Solutions of standard, sample and adjuvants were 
prepared at concentration of 100 µg mL-1. For this, 0.00252 
g of standard, 0.00466 g of sample e 0.00214 g of adjuvants 
(amount present in 0.00466 g of sample) were weighted and 
transferred to a 25 mL amber volumetric flask, added 5 mL 
of ethyl alcohol and kept in ultrasound equipment for 15 
minutes. Then, completed the volume with purified water 
and filtered the solution through filter paper. Dilutions to10 
µg mL-1 were made in 2 mL amber volumetric flask, 
completing the volume with solution of 20% of ethyl 
alcohol. The spectrums were obtained at 233 nm. 
 
Linearity 
 
From Ringbom curve, six points were chosen for the 
evaluation of the method linearity. It was prepared stock 
solution of standard at concentration of 100 µg mL-1 in the 
same way as detailed by the selectivity. Then, aliquots were 
transferred to a 2 mL volumetric flask and the volume was 
completed with solution of 20% of ethyl alcohol, in order to 
obtained solution at final concentrations of 4, 6, 8, 10, 12 
and 14 µg mL-1. The spectrum was obtained at 233 nm. This 
experiment was made in triplicate and in three different 
days. 
The linearity was evaluated by three methods: equation of 
least square, Analysis of Variance (ANOVA) and residue 
analysis. 
 
Precision 
 
 The precision evaluates the proximity between the results 
obtained by the intraday, interday, and interanalyst 
precisions (30). 
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Stock solutions of standard were prepared at concentration 
of 100 µg mL-1. Aliquots from this solution were transferred 
to a 2 mL amber volumetric flask and the volume was 
completed with solution of 20% of ethyl alcohol. Six results 
were obtained in the same day and in different days to test 
the intraday and interday precision, respectively. The 
interanalyst precision was made by a second analyst, 
however under the same conditions and equipment. 
The results were analyzed by relative standard deviation 
(RSD). 
 
 
 
 
 
Robustness 
 
The robustness evaluates small variations that can be 
performed in the analytic conditions of the method and it is 
important to describe this variations order to control them 
(30). 
Five parameters (Table 1) were modified from the normal 
condition and the results were compared. The parameters 
changed were: 
- Wavelength 
- Ultrasound time 
- Ethyl alcohol’s brand 
- Volumetric flask 
- Proportion of ethyl alcohol 
 
Table 1. Normal and changed conditions used in the robustness test and its statistical evaluation 
Parameters Normal Condition Changed Condition 
Test 
Fcal Ftab tcal ttab 
Wavelength 233 nm 235 nm 4.51 
19.00 
6.09 
2.78 
Ultrasound time 15 minutes 10 minutes 4.26 5.87 
Ethyl alcohol’s brand Brand A Brand B 6.81 1.68 
Volumetric flask Amber Colorless 4.00 4.98 
Proportion of ethyl alcohol 20% 18% 4.34 0.20 
 
Accuracy 
 
The accuracy shows the closeness of agreement between 
individuals’ values obtained in the method in relation to the 
real value (30). 
Stock solutions of rifaximin standard and sample were 
prepared at concentration of 100 µg mL-1. From each stock 
solution aliquots of 80 µL were transferred to a 2 mL amber 
volumetric flask and the volume was completing with 
purified water and 20% of ethyl alcohol obtaining a final 
concentration of 4 µg mL-1 in two amber volumetric flasks, 
one for the rifaximin standard and other for sample. After 
the aliquot of 80 µL of standard was transferred to a 2 mL 
amber volumetric flask and the contamination of sample was 
made by the addition of the 80 µL aliquot of standard 
obtaining final theoric concentration at 8 µg mL-1. The 
aliquot of 80 µL was kept but the amount of standard 
auditioned was altered by 120 µL and after 160 µL obtained 
final theoric concentrations at 10 µg mL-1 and 12 µg mL-1, 
respectively. 
The contamined sample method was explained in the Table 
2. 
 
Table 2. Preparation of solutions used in the accuracy parameter and results obtained in the standard recovery test 
 
Volume 
added of 
sample 
rifaximin 
(µL) * 
Volume 
added of 
standard 
rifaximin 
(µL)* 
Final theoric 
concentration 
(µg mL-1) 
Standard 
rifaximin 
recovered 
(µg mL-1) 
Recovery 
(%) 
Average 
recovery 
(%) 
RSD 
(%) 
Sample 80 - 4     
R1 80 80 8 4.02 100.63   
R2 80 120 10 6.02 100.33 100.56 0.21 
R3 80 160 12 8.06 100.73   
Standard - 80 4     
* at 100 µg mL-1 using volumetric flask of 2 mL 
 
The accuracy is calculated by percentage of recuperation of 
the standard from amount known added in the sample 
through of the equation (1): 
 
% 𝑅 = {
𝐶𝑟−𝐶𝑎
𝐶𝑝
}  𝑋 100               (1) 
 
Where: 
Cr = concentration of sample solution added in the standard 
(µg mL-1) 
Ca = concentration of sample solution 
Cp = theoric concentration of standard solution 
 
Results 
 
Method Development 
 
The sample weight from it was 369.79 g. The Figure 2A 
represents the weight values of twenty tablets and indicate 
by the limit maximum and minimum that all tablets are 
inside the value recommended by the Brazilian 
Pharmacopeia (12). 
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Figure 2. (A) Sample weight values of twenty tables analyzed and the minimum and maximum limits represented by the lines above and below, 
respectively. (B) Ringbom curve of rifaximin standard solution using purified water and 20% of ethyl alcohol. 
 
The solution of purified water with 20% of ethyl alcohol 
was choose to be diluent for rifaximin, because rifaximin 
showed suitable solubility and stability in this diluent, as 
shown in Table 3. 
 
Table 3. Absorbance values for all diluents tested in the experiment 
Diluent Concentration(µg mL-1) λ 
Absorbance values 
0 4 h 6 h 8 h 24 h 
Phosphate bufferpH 6.1 200 231 0.611 0.593 0.595 0.593 0.606 
Phosphate buffer pH 3.0 200 231 0.545 0.555 0.559 0.539 0.501 
Borate buffer pH 9.0 50 231 0.619 0.613 0.605 0.586 0.514 
Acetate buffer pH 3.0+SLS0.2% 100 231 0.483 0.417 0.420 0.411 0.303 
NaOH 0.001 mol L-1 200 231 0.879 0.822 0.789 0.771 0.687 
HCl 0.01 mol L-1 200 231 0.551 0.569 0.572 0.575 0.576 
Purified water + 10% ethyl alcohol 22 232 1.095 1.060 1.025 0.963 0.504 
Purified water + 20% ethyl alcohol 22 232 1.137 1.130 1.150 1.129 1.165 
ʎ= Wavelength; SLS= Sodium lauryl sulfate 
 
The Ringbom curve was made using 33 points that varied 
from 0.2 µg mL-1 to 200 µg mL-1 obtained by 
spectrophotometry in the ultraviolet region as shown in 
Figure 2B. 
From the Ringbom curve, six points were chosen to obtain 
the analytical curve utilized in the method validation. For 
the selection of the points were analyzed the linear 
association between them by the correlation coefficient (r) 
and the determination coefficient (R²). Therefore, the 
concentrations of 4, 6, 8, 10, 12 and 14 µg mL-1 were 
appropriate once they had better linearity of response. 
 
Method Validation 
Selectivity 
The Figure 1B shows the overlay of the standard, sample, 
and adjuvants spectrums using purified water and 20% of 
ethyl alcohol at concentration of 10 µg mL-1 obtained 
spectrophotometrically in the ultraviolet region. 
 
Linearity 
The linear regression equation (Figure 3A), where y is the 
absorbance values and x is the concentration values of 
rifaximin solutions, is y = 0.0523 x – 0.0057 estimated by 
the method of least square, with coefficient of determination 
(R²) equal to 0.9999 and correlation coefficient (r) equal to 
0.9999 for the standard rifaximin. 
 
 
Figure 3. (A) Analytical curve of standard rifaximin using purified 
water and 20% of ethyl alcohol at concentration of 4, 6, 8, 10, 12 
and 14 µg mL-1, obtained by spectrophotometry in the ultraviolet 
region. (B) Residues graphic versus reaction of standard rifaximin 
solution. 
 
The ANOVA (Table 4) was calculated through the values of 
the analytical curve. 
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Table 4. ANOVA of the absorbance values determined in the 
analytical curve of standard rifaximin by spectrophotometry in 
ultraviolet region 
Variation source DF SS Variance Fcalc Ftab (0.05) 
Among concentration 5 0.5735 0.114701 208.30* 3.11 
Linear regression 1 0.5734 0.573434 1041.35* 4.75 
Linearity deviation 4 0.0001 0.000018 0.03 3.26 
Inside (waste) 12 0.0006 0.000046 - - 
TOTAL  17 0.5741 - - - 
DF: degrees of freedom; SS: sum of squares. 
 
The residues analysis, represented in Figure 3B, examines 
the quality of setting in regression and ANOVA and helps to 
determine if the common least square suppositions have 
been attended. 
 
Precision 
 
The values of absorbance and RSD for the standard 
rifaximin solution obtained in this parameter are represented 
in Table 5. 
 
Table 5. Absorbance values of standard rifaximin solution 
obtained to the intraday, interday, and interanalyst precision 
parameters by spectrophotometry in the ultraviolet region 
Test Absorbance values RSD (%) 
 1 2 3 4 5 6  
Intraday 0.511 0.515 0.517 0.523 0.517 0.513 0.80 (n=6) 
Interday 
0.511 0.515 0.517 0.523 0.517 0.513 
1.19 (n=12) 
0.521 0.518 0.517 0.505 0.527 0.525 
Interanalyst 
0.521 0.518 0.517 0.505 0.527 0.525 
1.19 (n=12) 
0.518 0.518 0.517 0.523 0.523 0.510 
 
Robustness 
 
The values calculated through test F and test t for the 
variations realized in the robustness parameter are 
represented in the Table 1. 
 
Accuracy 
 
The values obtained through the recovery test by 
spectrophotometry in the ultraviolet region are described in 
Table 2. 
 
Discussion 
 
Selectivity 
 
The selectivity was proved by the comparison of the 
absorbance values between the standard and sample 
rifaximin solutions. The sobreposition of the standard, 
sample, and adjuvants spectrum (Figure 1B) indicate that the 
adjuvants present in the sample composition do not 
influence the results obtained in the wavelength 233 nm. 
Therefore, the analytical method developed is selective to 
detection of rifaximin in the conditions described. 
 
Linearity 
 
The analytical curve demonstrates the proportionality 
between absorbance versus concentration. The linearity was 
emphasized by the correlation coefficient (r) equal 0.9999 
and determination coefficient (R²) equal 0.9999 and this 
result is in line with RDC 166 (2017) that specifically the 
correlation coefficient must be greater than 0.990 (30). 
The ANOVA indicate (i) there is difference between the 
absorbance values of the different concentrations utilized as 
calculated F is greater than tabulated F; (ii) there is a linear 
regression between the six points because calculated F is 
greater than tabulated F; (iii) there is not linearity deviation, 
as calculated F is lower than tabulated F. All the values are 
represented in Table 1. 
From de Gauss curve, that shows variability, one standard 
deviation is equivalent to 1.96 upwards or downwards. 
Taking residues graphic, it should be noted the variability 
between the points for the standard rifaximin solution is into 
the range -0.05 and +0.05, indicating that the variability 
between the points is accepted. 
The residues graphic showed that the common least square 
suppositions and ANOVA were met. Then this method is 
linear and will produce estimation of non addicted 
coefficient with minimum variance. 
 
Precision 
 
According to the results obtained by the precision 
parameter, it should be noted the RSD values (RSD %), for 
the intraday, interday, and interanalyst precision are below 
2%, therefore the method is precise. 
 
Robustness 
 
The test t show that t value is greater than t critical, or, t is 
significant and there is difference between the results for the 
alterations that were made at the wavelength, ultrasound 
time and volumetric flask utilized. So, changes in these 
parameters require caution for the develop method. 
It is extremely important to make the analysis at wavelength 
of 233 nm because rifaxinin has maximum absorption in this 
wavelength, then a minimum variation in this wavelength 
could mean a risk for the final result. 
Ultrasound time must be standardized in 15 minutes because 
below this time the rifaximin solubility could be 
compromised and may display inadequate results. 
Rifaximin is a compound photosensitive that explains why 
there was difference between the results from amber and 
colorless volumetric flask. 
Alterations made in the parameters ethyl alcohol brand and 
ethyl alcohol proportion do not present a great influence for 
the method developed, as the t value is lower than t critical 
or, t is not significant, then there is not difference between 
the results. 
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Even though the ethyl alcohol brand can be changed, the 
alteration made in proportion of ethyl alcohol did not have 
significant difference in the results, but the alteration was 
minimal, so caution must be taken in variation in this 
proportion, as in the development of the method the 
proportion of 10% of ethyl alcohol was tested but the results 
were unsatisfactory. 
 
Accuracy 
 
The values suggested by the Association of Official 
Analytical Chemists (AOAC) (31) such as acceptable to the 
recovery range were represented in Table 6. 
For the analysis of pharmaceutical products, the accuracy 
specifications follow the range 98-102%. The value obtained 
for the recovery test was equal to 100.56% represented in 
Table 2, then there is evidence that the method developed is 
accurate. 
 
Conclusion 
 
The miniaturized and green method for the quantification of 
rifaximin in tablets by spectrophotometry in the ultraviolet 
region was developed and validated following the 
parameters: selectivity, linearity, precision, accuracy and 
robustness. This method presents advantages because it is 
fast, simple, requires fewer amounts of sample and solvents, 
generates minimum amount of waste and causes minimum 
prejudice to the environment and operator. Then, this 
method can be utilized in the routine analysis in the Quality 
Control more eco-friendly and sustainable. 
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